相关实验视频
Updated: Jul 4, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
确定性结肠炎患者的最佳治疗目标:随机对照VERDICT试验的理由,设计,方案和临时分析
Vipul Jairath1,2, Guangyong Zou2,3, Zhongya Wang2
1Department of Medicine, Division of Gastroenterology; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada vjairath@uwo.ca.
这项研究比较了性结肠炎 (UC) 的三个治疗目标,以找到减少并发症的最佳目标. 在UC患者中,实现组织学缓解可能比单独内镜缓解提供更好的结果.
科学领域:
- 胃肠病学 胃肠病学
- 临床试验 临床试验
- 炎症性肠道疾病研究研究
背景情况:
- 性结肠炎 (UC) 的治疗目标包括症状,内镜和组织学.
- 观察数据表明,组织学缓解可能比单独的内镜缓解更能减少UC并发症.
- VERDICT试验调查了UC管理的最佳治疗目标.
研究的目的:
- 确定中度至重度性结肠炎 (UC) 患者的最佳治疗目标.
- 基于实现不同的缓解目标,比较UC相关并发症的风险.
主要方法:
- 这是一项多中心前性随机研究,涉及660名UC患者.
- 患者被随机分配到症状缓解,内镜缓解与症状缓解,或组织学缓解与内镜和症状缓解.
- 用维多利祖马布治疗的升级是由治疗算法指导的,结果在16周,32周或48周后进行评估.
主要成果:
- 主要结果是从目标实现到UC相关并发症的时间.
- 使用Cox比例危险模型,比较症状缓解和组织学缓解组之间的时间至并发症.
- 研究结果正在等待,试验完成后将传播.
结论:
- VERDICT试验旨在确定性结肠炎最有效的治疗目标.
- 结果将为临床实践提供有关UC管理策略的信息.
- 实现最佳目标对于最大限度地减少长期UC并发症至关重要.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
06:28E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents